{"id":389010,"date":"2024-12-19T00:00:00","date_gmt":"2024-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2024-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:39","modified_gmt":"2026-03-31T10:27:39","slug":"dlsfon0005-2024-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2024-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2024\/","title":{"rendered":"Multiple Myeloma | Disease Landscape and Forecast | G7 | 2024"},"content":{"rendered":"<p>Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and\/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-targeted agents (e.g., Johnson &#038; Johnson Innovative Medicine\u2019s Darzalex) or other chemotherapy-based regimens. The preferred first-line treatment is bortezomib combined with lenalidomide and dexamethasone. CAR T-cell therapies (e.g., Bristol Myers Squibb \/ Bluebird Bio\u2019s Abecma, Johnson &#038; Johnson Innovative Medicine \/ Legend Biotech\u2019s Carvykti) and bispecific antibodies (e.g., Johnson &#038; Johnson Innovative Medicine\u2019s Tecvayli and Talvey, Pfizer\u2019s Elrexfio) have expanded the options available for relapsed \/ refractory disease. Therapies in late-phase development will, if approved, further fragment the treatment of multiple myeloma.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the key drug-treatable populations? How will drug-treatment rates change over the 2023-2033 forecast period?<\/li>\n<li>How will the current treatment landscape change over the forecast period, and what impact will generic entry have on the market?<\/li>\n<li>Which emerging therapies are the most promising for multiple myeloma?<\/li>\n<li>What factors are driving the growth of the multiple myeloma therapy market, and how will it evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389010","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389010\/revisions"}],"predecessor-version":[{"id":575859,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389010\/revisions\/575859"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}